Molecular Characterization of Extended-Spectrum Beta-Lactamase-Producing Extra-Intestinal Pathogenic Escherichia coli Isolated in a University Teaching Hospital Dakar-Senegal

Research Article

Austin J Microbiol. 2022; 7(1): 1040.

Molecular Characterization of Extended-Spectrum Beta-Lactamase-Producing Extra-Intestinal Pathogenic Escherichia coli Isolated in a University Teaching Hospital Dakar-Senegal

Dossouvi KM1*, Sambe-Ba B2, Lo G1,3, Cissé A2, Ba-Diallo A1,3, Ndiaye I2, Dieng A1, Ndiaye SML1, Fall C2, Tine A1, Karam F1, Diagne-Samb H1, Ngom-Cisse S1, Diop-Ndiaye H1,3, Toure-Kane C3, Gaye-Diallo A1,3, Mboup S1,3, Boye CSB1, Dièye Y2, Seck A2,4 and Camara M1,3

1Bacteriology-Virology Laboratory, National University Hospital, Aristide Le Dantec, Dakar, Senegal

2Pole of Microbiology, Institut Pasteur de Dakar, Senegal

3Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Dakar, Senegal

4Medical Analysis Laboratory, Institut Pasteur de Dakar, Senegal

*Corresponding author: Dossouvi KM, Bacteriology-Virology Laboratory, National University Hospital, Aristide Le Dantec– 30, avenue Pasteur-BP7325-Dakar, Sénégal

Received: July 29, 2022; Accepted: August 25, 2022; Published: September 01, 2022

Abstract

Extra-Intestinal Pathogenic Escherichia coli (ExPEC) is a predominant Gram-negative bacterial pathogen and is responsible of several diseases including Urinary Tract Infections (UTI), nosocomial pneumonia, and neonatal meningitis. ExPEC isolates are often multidrug resistant and clones producing Extended-Spectrum Beta-Lactamases (ESBL) are increasingly reported all over the world.

Seventy-eight clinical ExPEC strains (49 Community-Acquired (CA) and 29 Hospital-Acquired (HA)) were selected for this study. The majority was from UTIs (n=51), while the rest (n=27) was from pus, sputum, bronchial fluid and vaginal samples (non-uropathogenic ExPEC). Antibiotic susceptibility testing was performed using the Kirby-Bauer disc diffusion method. Standard polymerase chain reaction was used to screen major ESBL genes (blaCTX-M, blaOXA-1, blaTEM, blaSHV) and blaCTX-M variants (blaCTX-M-1, blaCTX-M-9, blaCTX-M-15, blaCTX-M-25).

All the tested isolates were resistant to ampicillin, ticarcillin, amoxicillin/ clavulanic acid combination, cefalotin, cefotaxime, ceftazidime, cefepime and aztreonam, but showed a high susceptibityto fosfomycin (98.7%, n = 77), ertapenem (96.2%, n = 75), and imipenem (100%). Moreover, isolates harbored at least one ESBL gene, including blaCTX-M (98.7%), blaOXA-1 (78.2%), blaTEM (44.9%) and blaSHV (3.8%). The CTX-M variants were also found with the predominance of blaCTX-M-1 (89.7%) and blaCTX-M-15 (89.7%) followed by blaCTX-M-9 (11.5%).

Despite the resistance to most of the tested antibiotics, ExPEC isolates showed fortunately good susceptibility to fosfomycin and carbapenems. blaCTX-M1, blaCTX-M15 and blaOXA-1 seem to be E.coli major ESBL genes circulating in Senegal. The high level of resistance to antimicrobials observed stresses the need of establishing an epidemiological surveillance of antimicrobial resistance in both community and hospital settings.

Keywords: Escherichia coli; Extended spectrum beta-lactamase; Hospital; Dakar-senegal

Abbreviations

AMR: Antimicrobial Resistance; BLI: Beta-Lactamase Inhibitors; CA: Community-Acquired Bacteria; E. coli: Escherichia coli; ESBL: Extended-Spectrum Beta-Lactamases; ExPEC: Extra-Intestinal Pathogenic Escherichia coli; HA: Hospital-Acquired Bacteria; HALD: Aristide le Dantec University Teaching Hospital; MDR: Multidrug Resistant; No-UPEC: No-Uropathogenic Escherichia coli; UPEC: Uropathogenic Escherichia coli; UTI: Urinary Tract Infections

Introduction

Escherichia coli, a common bacteria found in various parts of the human body, is also the predominant bacterial species responsible for Community-Acquired (CA) and Hospital-Acquired (HA) infections at all ages in human [1]. Human pathogenic E. coli strains are classified into two large groups, strains responsible for intestinal infections and those causing extra-intestinal diseases (ExPEC) [2,3].

ExPECs are among the most common Gram-negative bacterial pathogens affecting Human with diverse infections, including Urinary Tract Infections (UTI), bacteremia, meningitis, nosocomial respiratory infections, peritonitis, prostatitis, skin and soft tissue infections [4-6].

In addition, Multidrug Resistant (MDR) ExPECs are now common both in community-acquired and hospital-acquired infections, including resistance to ß-lactams, which are the commonly used antibiotics in human and animal health. The ß-lactams resistance is mainly mediated by production of extended-spectrum betalactamases [7-9]. These enzymes hydrolyze penicillins, cephalosporins (first, second, third, and fourth generation), and monobactams, but are generally inactive against cephamycins and carbapenems. ESBLs are generally inhibited by Beta-Lactamase Inhibitors (BLI) [10,11]. A worrying fact is that mobile genetic elements that harbor ESBL genes also carry others genes conferring resistance to quinolones, aminoglycosides and even carbapenems [12-15].

ESBL-producing ExPECs infections are responsible of extended hospital stays, accompanying high cost and mortality and morbidity [2]. Hence, the importance to establish innovative diagnostic toolkits and performant surveillance system for early detection and monitoring of ExPECs cases, especially in developing countries. In this study, we investigated the antibiotic resistance profile and the ESBL genes carried by ESBL-producting ExPEC isolated at the laboratory of bacteriology laboratory, Aristide le Dantec University Teaching Hospital (HALD) in Dakar, Senegal. Additionally, we compared CA to HA, and uropathogenic E. coli (UPEC) to No- Uropathogenic ExPEC Isolates (No-UPEC).

Material and Methods

Bacterial Isolates

This is a retrospective study and all ExPEC isolates analyzed in this study were collected between January 1st, 2018 and December 31th, 2020 at the Hospital Laboratory of HALD during routine activities and stored at -80°C. Seventy-eight no-duplicate strains were randomly selected from the Laboratory. Strains were isolated from urine (UPEC, n = 51), pus, sputum, bronchial fluid and vaginal samples (no-uropathogenic ExPEC, n = 27). Of the 78 strains, 49 and29 were CA and HA respectively. Culture and Isolation were done based on gold standard microbiological tests and identification by using Api 20E for Enterobacteriaceae (bioMérieux France).

Antibiotic Susceptibility Testing

Antibiotic susceptibility testing was performed using the Kirby- Bauer disc diffusion method and results were interpreted according to the committee of the French society of microbiology (CA-SFM, 2020) recommendations. Briefly, bacterial suspensions were prepared at 0.5 McFarland and inoculated onto Mueller-Hinton agar for an overnight incubation at 37°C. These following antibiotic disks were tested: ampicillin (AMP, 10μg), ticarcillin (TIC, 75μg), amoxicillin-clavulanic acid (AMC, 20/10μg), cefalotin (CEF, 30 μg), cefoxitin (FOX, 30 μg), cefotaxime (CTA, 30μg), ceftazidime (CAZ, 30μg), cefepime (CEP, 30μg), aztreonam (AZT, 30μg), imipenem (IMP, 10μg), ertapenem (ERT, 10μg), Nalidixic acid (NAL, 30μg ), ciprofloxacin (CIP, 5 μg), gentamicin (GEN, 10 μg), amikacin (AMI, 30 μg), fosfomycin (FOS, 50 μg), tetracycline (TET, 30 μg) and sulfamethoxazole-trimethoprim (TMS, 1.25μg / 23.75μg). The E. coli ATCC 25922 was used for quality control. ESBL production was appreciated by double-disk synergy test with disks of amoxicillin-clavulanic acid surrounded at a radius of 30 mm by cefepime, ceftriaxone, ceftazidime and aztreonam.

DNA Extraction

Bacterial DNA extraction was performed mechanically by thermal choc. Briefly, a well-separated bacterial colony was dispersed in a tube contained 1ml of sterile distilled water, vortexed, boiled for 15 minutes at 100°C and centrifuged at 13,200 rpm for 10 min. The supernatant was carefully recovered, aliquoted and stored at -20°C until used. To confirm results, extraction was done by Qiagen kit (DNeasy Blood & Tissue Kit (50) Cat. No. / ID: 69504).

ESBL Genes Amplification

A simplex end-point PCR was performed (on Thermocycler 2720, Applied Biosystems, Lincoln Centre Drive, Foster City, California 94404, USA) to detect ESBL genes. Specific primer pairs (Table 1) were used to amplify ESBL genes (blaCTX-M, blaCTX-M-1, blaCTX-M-9, blaCTX-M-15, blaCTX-M-25, blaOXA-1, blaTEM, blaSHV). Each reaction included positive and negative controls. PCRs were carried out in 20 μl reaction volume (2.5 μl DNA + 17.5 μl Master MixFIREPol®). The amplification program consisted of an initial denaturation at 95°C for 3min., 35 PCR cycles (denaturation: 94°C, 30sec., 72°C, 60sec.) and a final elongation at 72°C for 7min. Ten micro liters of each amplicon were separated on 2% agarose gel in 1X TAE buffer for 35 min at 135 volts and the amplified fragment detected using a GelDoc imager (BioRad).